Summit Therapeutics (NASDAQ: SMMT) was one of the stars of the biotech industry. The company's shares soared following a ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

UK-based Trimtech Therapeutics, a biotech harnessing targeted protein degradation (TPD) for neurodegenerative diseases, has announced the closing of its $31 million seed funding round.

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

A Cambridge-based biotechnology firm developing antibody-based KnotBody drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, has raised £58m in a Series A financing.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

In this week’s edition of the biotech bi-weekly, learn more about CRAIC technologies’ 5D Spectral Surface Mapping solution, ...